The Federal Commission for the Protection against Sanitary Risks (Cofepris) authorized this Friday the emergency use of molnupiravir, Merck & Co’s pill against COVID-19.
The agency pointed out that the drug requires a prescription for its application. It will be used in patients who present a mild or moderate COVID picture and have a high risk of complications.He explained that the ‘path’ to grant this authorization began a few days ago, on December 23, 2021, when he exchanged “technical information” with regulatory bodies from other countries.
“This knowledge transfer process is carried out thanks to reliance, or regulatory convergence, declared a priority in Cofepris in August last year,” he added in a release.President Andrés Manuel López Obrador said, in his ‘morning’ this Friday, that the drug will be administered in public hospitals in Mexico.
Which patients can receive this drug?
Cofepris detailed that the use of the drug will be made in patients who meet these characteristics:
- Mild to moderate COVID-19 in adults with a positive test
- Do not require supplemental oxygen
- Have at least one risk factor for developing severe COVID-19 (including hospitalization or death)
- For whom authorized COVID-19 alternative treatment options are not accessible or clinically appropriate
- The pill attacks the genetic material of the pathogen by introducing ‘ errors’ in its sequence, causing it to disappear
- The treatment proved to be safe and effective in adults who are at risk of developing severe COVID illness, i.e., in danger of being hospitalized.
- Molnupiravir reduced the rate of hospitalization and death by 50 percent in patients with mild to moderate COVID.
How does molnupiravir attack the SARS-CoV-2 virus?
Molnupiravir, which is cheaper to produce than other drugs, is also already supported by licensing agreements for generic drug companies to produce the pill.With information from Bloomberg
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here